Quality of life and survival in patients with uterine carcinosarcoma: A tertiary center observational study
Objective: This study aimed to assess the QoL in patients with uterine carcinosarcoma (UCS) and identify factors influencing survival. Methods: A prospective cohort study was conducted of patients with UCS who were treated between 2016 and 2022 in a Dutch academic hospital. QoL was evaluated using t...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Gynecologic Oncology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352578925000049 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850086362283245568 |
|---|---|
| author | Eveline N.B. Pham Caroline B. van den Berg Ingrid Boere Vera de Geus Juanita A. Haagsma Marianne Maliepaard Jan Willem M. Mens Floris H. Groenendijk Heleen J. van Beekhuizen |
| author_facet | Eveline N.B. Pham Caroline B. van den Berg Ingrid Boere Vera de Geus Juanita A. Haagsma Marianne Maliepaard Jan Willem M. Mens Floris H. Groenendijk Heleen J. van Beekhuizen |
| author_sort | Eveline N.B. Pham |
| collection | DOAJ |
| description | Objective: This study aimed to assess the QoL in patients with uterine carcinosarcoma (UCS) and identify factors influencing survival. Methods: A prospective cohort study was conducted of patients with UCS who were treated between 2016 and 2022 in a Dutch academic hospital. QoL was evaluated using the EORTC QLQ-C30 and QLQ-EN24 questionnaires at baseline, end of treatment, and at one, two, and five years after treatment. Outcomes were described as mean scores in functioning and symptom domains. The mean scores of the QLQ-C30 were compared to those of a matched group from the general Dutch population. Clinical data were collected. Factors influencing survival were assessed via Cox proportional hazards models. Results: The study included 64 patients, 56 of them participated in the QoL questionnaires. The median progression-free survival was 13 months, and overall survival was 20 months. QoL was significantly lower in all functional domains at one year after treatment compared to members of the general population. The most affected functioning domains were physical, role, cognitive, and social functioning and symptoms like fatigue, pain, and lymphedema. Long-term QoL remained compromised, with global health and insomnia notably impaired even five years after treatment. Significant prognostic factors for better overall survival included lower FIGO stage, surgery, and chemotherapy. Conclusions: Patients with UCS experience significant deterioration in QoL. Despite extensive treatment, QoL remains poor, emphasizing the need for integrating QoL considerations into treatment decisions to balance the benefits of treatment with potential QoL impairments. |
| format | Article |
| id | doaj-art-d5bc42a874824e1cb4e430168c4f1c4f |
| institution | DOAJ |
| issn | 2352-5789 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Gynecologic Oncology Reports |
| spelling | doaj-art-d5bc42a874824e1cb4e430168c4f1c4f2025-08-20T02:43:29ZengElsevierGynecologic Oncology Reports2352-57892025-02-015710167910.1016/j.gore.2025.101679Quality of life and survival in patients with uterine carcinosarcoma: A tertiary center observational studyEveline N.B. Pham0Caroline B. van den Berg1Ingrid Boere2Vera de Geus3Juanita A. Haagsma4Marianne Maliepaard5Jan Willem M. Mens6Floris H. Groenendijk7Heleen J. van Beekhuizen8Department of Gynecologic Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Molewaterplein 40, 3015 GD Rotterdam, the Netherlands; Corresponding author at: Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.Department of Gynecologic Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Molewaterplein 40, 3015 GD Rotterdam, the NetherlandsDepartment of Medical Oncology, Erasmus MC Cancer Center, Molewaterplein 40, 3015 GD Rotterdam, the NetherlandsDepartment of Gynecologic Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Molewaterplein 40, 3015 GD Rotterdam, the NetherlandsDepartment of Public Health, Erasmus MC University Medical Center, Molewaterplein 40, 3015 GD Rotterdam, the NetherlandsDepartment of Gynecologic Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Molewaterplein 40, 3015 GD Rotterdam, the NetherlandsDepartment of Radiotherapy, Erasmus MC Cancer Institute, Molewaterplein 40, 3015 GD Rotterdam, the NetherlandsDepartment of Pathology, Erasmus MC Cancer Institute, Molewaterplein 40, 3015 GD Rotterdam, the NetherlandsDepartment of Gynecologic Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Molewaterplein 40, 3015 GD Rotterdam, the NetherlandsObjective: This study aimed to assess the QoL in patients with uterine carcinosarcoma (UCS) and identify factors influencing survival. Methods: A prospective cohort study was conducted of patients with UCS who were treated between 2016 and 2022 in a Dutch academic hospital. QoL was evaluated using the EORTC QLQ-C30 and QLQ-EN24 questionnaires at baseline, end of treatment, and at one, two, and five years after treatment. Outcomes were described as mean scores in functioning and symptom domains. The mean scores of the QLQ-C30 were compared to those of a matched group from the general Dutch population. Clinical data were collected. Factors influencing survival were assessed via Cox proportional hazards models. Results: The study included 64 patients, 56 of them participated in the QoL questionnaires. The median progression-free survival was 13 months, and overall survival was 20 months. QoL was significantly lower in all functional domains at one year after treatment compared to members of the general population. The most affected functioning domains were physical, role, cognitive, and social functioning and symptoms like fatigue, pain, and lymphedema. Long-term QoL remained compromised, with global health and insomnia notably impaired even five years after treatment. Significant prognostic factors for better overall survival included lower FIGO stage, surgery, and chemotherapy. Conclusions: Patients with UCS experience significant deterioration in QoL. Despite extensive treatment, QoL remains poor, emphasizing the need for integrating QoL considerations into treatment decisions to balance the benefits of treatment with potential QoL impairments.http://www.sciencedirect.com/science/article/pii/S2352578925000049Uterine carcinosarcomaEndometrial cancerQuality of lifeSurvival |
| spellingShingle | Eveline N.B. Pham Caroline B. van den Berg Ingrid Boere Vera de Geus Juanita A. Haagsma Marianne Maliepaard Jan Willem M. Mens Floris H. Groenendijk Heleen J. van Beekhuizen Quality of life and survival in patients with uterine carcinosarcoma: A tertiary center observational study Gynecologic Oncology Reports Uterine carcinosarcoma Endometrial cancer Quality of life Survival |
| title | Quality of life and survival in patients with uterine carcinosarcoma: A tertiary center observational study |
| title_full | Quality of life and survival in patients with uterine carcinosarcoma: A tertiary center observational study |
| title_fullStr | Quality of life and survival in patients with uterine carcinosarcoma: A tertiary center observational study |
| title_full_unstemmed | Quality of life and survival in patients with uterine carcinosarcoma: A tertiary center observational study |
| title_short | Quality of life and survival in patients with uterine carcinosarcoma: A tertiary center observational study |
| title_sort | quality of life and survival in patients with uterine carcinosarcoma a tertiary center observational study |
| topic | Uterine carcinosarcoma Endometrial cancer Quality of life Survival |
| url | http://www.sciencedirect.com/science/article/pii/S2352578925000049 |
| work_keys_str_mv | AT evelinenbpham qualityoflifeandsurvivalinpatientswithuterinecarcinosarcomaatertiarycenterobservationalstudy AT carolinebvandenberg qualityoflifeandsurvivalinpatientswithuterinecarcinosarcomaatertiarycenterobservationalstudy AT ingridboere qualityoflifeandsurvivalinpatientswithuterinecarcinosarcomaatertiarycenterobservationalstudy AT veradegeus qualityoflifeandsurvivalinpatientswithuterinecarcinosarcomaatertiarycenterobservationalstudy AT juanitaahaagsma qualityoflifeandsurvivalinpatientswithuterinecarcinosarcomaatertiarycenterobservationalstudy AT mariannemaliepaard qualityoflifeandsurvivalinpatientswithuterinecarcinosarcomaatertiarycenterobservationalstudy AT janwillemmmens qualityoflifeandsurvivalinpatientswithuterinecarcinosarcomaatertiarycenterobservationalstudy AT florishgroenendijk qualityoflifeandsurvivalinpatientswithuterinecarcinosarcomaatertiarycenterobservationalstudy AT heleenjvanbeekhuizen qualityoflifeandsurvivalinpatientswithuterinecarcinosarcomaatertiarycenterobservationalstudy |